granoblastinen

Granoblastin is a synthetic analog of the human growth hormone-releasing hormone (GHRH), a peptide hormone that stimulates the pituitary gland to release growth hormone (GH). It is used primarily in the treatment of growth hormone deficiency (GHD) in adults and children. Granoblastin is administered via subcutaneous injection and is available in various formulations, including lyophilized powder for injection and pre-filled syringes.

The mechanism of action of granoblastin involves binding to specific receptors on the pituitary gland, leading to the release of GH. This increase in GH levels helps to restore normal growth hormone function, which is essential for various physiological processes such as metabolism, bone growth, and muscle development.

Granoblastin is indicated for the treatment of GHD in adults and children, as well as for the management of short stature in adults with GHD. It is also used in the treatment of Turner syndrome, a genetic disorder characterized by short stature, and in the management of other conditions associated with growth hormone deficiency.

Common side effects of granoblastin include headache, nausea, and injection site reactions. Serious side effects are rare but can include gallbladder disease, pancreatitis, and tumors of the pituitary gland. As with any medication, it is important to use granoblastin under the guidance of a healthcare professional and to follow the prescribed dosage and administration schedule.